Engineering Live biotherapeutics to treat complex respiratory diseases

Maria Lluch Senar, Founder and Chief Scientific Officer at Pulmobiotics SL, discusses the research on engineering Live Biotherapeutics in order to expose antigens or deliver therapeutic agents to treat complex respiratory diseases.

Otolaryngology, Pneumology, Video

During the 8th annual Microbiome Movement Drug Development Europe, held in Barcelona (Spain), Microbiomepost sat down with Maria Lluch Senar, Founder and Chief Scientific Officer at Pulmobiotics SL, to discuss the research on engineering Live Biotherapeutics in order to expose antigens or deliver therapeutic agents to treat complex respiratory diseases.

Most recent

Nutrition

HCPs Area

World Microbiome Day 2023: Microbes and Food

Probiotics for female indications: Impact of Probi® probiotics for bone health support

Industry

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

Read more about LBP

Nutrition

Engineering Live biotherapeutics to treat complex respiratory diseases

Most recent

Microbial signatures for food traceability: ensuring quality and safety from fermented wines to novel insect-based foods

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

Microbiota linked to susceptibility to necrotizing enterocolitis in preemies

HCPs Area

World Microbiome Day 2023: Microbes and Food

Probiotics for female indications: Impact of Probi® probiotics for bone health support

Industry

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

Microbial signatures for food traceability: ensuring quality and safety from fermented wines to novel insect-based foods

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

Probiotics as adjuvant therapy in cancer immunotherapy: from Biofarma Group

Microbiota linked to susceptibility to necrotizing enterocolitis in preemies

Microbiome’s implications in recurrent pregnancy loss

QIAGEN and McGill University partner to drive innovation in microbiome research

Dietary fiber, bloutia, and mucus function: uncovering potential for Next-Generation Probiotics

EnteroBiotix’s EBX-102 shows promising Phase 1b results for liver cirrhosis treatment